Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Castration-Resistant Prostate Cancer Patients 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

aldesleukin 22Sunitinib 21Bevacizumab 16Interleukin-2 14Everolimus 14Interferon-alpha 13Gemcitabine 13Cyclophosphamide 13fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 9Sorafenib 8Filgrastim 8Axitinib 8Nivolumab 7pembrolizumab 6Ipilimumab 6Doxorubicin 6Carboplatin 6sargramostim 5cabozantinib 5Capecitabine 5Thalidomide 4Tacrolimus 4Radiotherapy 4Radiosurgery 4Neoadjuvant Therapy 4Mycophenolic Acid 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Neoplasms × irofulven × Clear all
NCT00003390 2013-06-21

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡